Literature DB >> 27582111

Propensity Score-Based Analysis of Percutaneous Closure Versus Medical Therapy in Patients With Cryptogenic Stroke and Patent Foramen Ovale: The IPSYS Registry (Italian Project on Stroke in Young Adults).

Alessandro Pezzini1, Mario Grassi1, Corrado Lodigiani1, Rosalba Patella1, Carlo Gandolfo1, Andrea Zini1, Maria Luisa DeLodovici1, Maurizio Paciaroni1, Massimo Del Sette1, Antonella Toriello1, Rossella Musolino1, Rocco Salvatore Calabrò1, Paolo Bovi1, Alessandro Adami1, Giorgio Silvestrelli1, Maria Sessa1, Anna Cavallini1, Simona Marcheselli1, Domenico Marco Bonifati1, Nicoletta Checcarelli1, Lucia Tancredi1, Alberto Chiti1, Elisabetta Del Zotto1, Giampaolo Tomelleri1, Alessandra Spalloni1, Elisa Giorli1, Paolo Costa1, Giacomo Giacalone1, Paola Ferrazzi1, Loris Poli1, Andrea Morotti1, Valeria Piras1, Maurizia Rasura1, Anna Maria Simone1, Massimo Gamba1, Paolo Cerrato1, Maria Luisa Zedde1, Giuseppe Micieli1, Maurizio Melis1, Davide Massucco1, Davide Guido1, Valeria De Giuli1, Silvia Bonaiti1, Cataldo D'Amore1, Sara La Starza1, Licia Iacoviello1, Alessandro Padovani1.   

Abstract

BACKGROUND: We sought to compare the benefit of percutaneous closure to that of medical therapy alone for the secondary prevention of embolism in patients with patent foramen ovale (PFO) and otherwise unexplained ischemic stroke, in a propensity scored study. METHODS AND
RESULTS: Between 2000 and 2012, we selected consecutive first-ever ischemic stroke patients aged 18 to 45 years with PFO and no other cause of brain ischemia, as part of the IPSYS registry (Italian Project on Stroke in Young Adults), who underwent either percutaneous PFO closure or medical therapy for comparative analysis. Primary end point was a composite of ischemic stroke, transient ischemic attack, or peripheral embolism. Secondary end point was brain ischemia. Five hundred and twenty-one patients qualified for the analysis. The primary end point occurred in 15 patients treated with percutaneous PFO closure (7.3%) versus 33 patients medically treated (10.5%; hazard ratio, 0.72; 95% confidence interval, 0.39-1.32; P=0.285). The rates of the secondary end point brain ischemia were also similar in the 2 treatment groups (6.3% in the PFO closure group versus 10.2% in the medically treated group; hazard ratio, 0.64; 95% confidence interval, 0.33-1.21; P=0.168). Closure provided a benefit in patients aged 18 to 36 years (hazard ratio, 0.19; 95% confidence interval, 0.04-0.81; P=0.026) and in those with a substantial right-to-left shunt size (hazard ratio, 0.19; 95% confidence interval, 0.05-0.68; P=0.011).
CONCLUSIONS: PFO closure seems as effective as medical therapy for secondary prevention of cryptogenic ischemic stroke. Whether device treatment might be more effective in selected cases, such as in patients younger than 37 years and in those with a substantial right-to-left shunt size, deserves further investigation.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  atrial septum; follow-up studies; patent foramen ovale; secondary prevention; stroke

Mesh:

Substances:

Year:  2016        PMID: 27582111     DOI: 10.1161/CIRCINTERVENTIONS.115.003470

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  3 in total

1.  Percutaneous closure versus medical therapy for stroke with patent foramen Ovale: a systematic review and meta-analysis.

Authors:  Xin-Lin Zhang; Li-Na Kang; Lian Wang; Biao Xu
Journal:  BMC Cardiovasc Disord       Date:  2018-03-02       Impact factor: 2.298

2.  Patent foramen ovale closure versus medical therapy for stroke prevention: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Gary Tse; William K K Wu; Jenny Chi Ling Lai; Mengqi Gong; George Bazoukis; Wing Tak Wong; Sunny Hei Wong; Konstantinos Lampropoulos; Adrian Baranchuk; Lap Ah Tse; Yunlong Xia; Guangping Li; Martin C S Wong; Yat Sun Chan; Nan Mu; Mei Dong; Tong Liu
Journal:  F1000Res       Date:  2017-12-27

3.  Long-term efficacy after closure of patent foramen ovale for ischemic neurological events in young adults: A systematic review and meta-analysis.

Authors:  Liang Xu; Xuemei Pan; Chang Zhou; Jie Li; Fangyuan Wang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.